Sector News

Private equity fund buys out sterile injectables maker LSNE

March 28, 2017
Life sciences

Sterile drug manufacturing is a growth area, and a London-based investment fund has bitten off a piece of it with the acquisition of a U.S. CDMO that specializes in the field.

Management and private equity firm Permira is buying out Lyophilization Services of New England (LSNE) for an undisclosed sum. LSNE has three manufacturing facilities located in New Hampshire that provide lyophilization services to pharma, biotech and medical device clients. It specializes in small to medium-size batches.

Matt Halvorsen, who founded the company in 1997, will retain a significant ownership position and continue to be its CEO, Permira said. Claes Glassell, the former CEO of CMC Biologics, will become chairman of the board, provide management support and help with the company’s growth strategy.

There has been a significant amount of growth in contract sterile manufacturing in recent years as a growing proportion of new drugs are sterile injectables. In 2015, Pfizer snapped up sterile injectable and biosimilar specialist Hospira for $15 billion.

And last year, Germany’s Fresenius Kabi announced it would invest $250 million in its manufacturing site in Melrose Park, Illinois into a showcase for its sterile injectable capabilities. That came after Fresenius agreed to buy a nearly new 115,000-square-foot plant and small portfolio of products from Becton Dickinson, which built the plant in Wilson, North Carolina as a way to boost its syringe manufacturing sales.

Shanghai Fosun Pharmaceutical Group last year struck a deal to buy an 86% stake in India’s Gland Pharma for $1.35 billion. Approval of that deal by Indian regulators was recently delayed. Hyderabad-based Gland has four manufacturing sites in India that handle a wide variety of container-types and fillings.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach